NASDAQ:CGIX
Delisted
Cancer Genetics Stock News
$1.08
+0 (+0%)
At Close: May 27, 2022
Cancer Genetics and StemoniX Announce Merger Closing
06:30am, Wednesday, 31'st Mar 2021
Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
09:15am, Thursday, 25'th Mar 2021
Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
04:15pm, Thursday, 04'th Mar 2021
RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
04:45pm, Tuesday, 16'th Feb 2021
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today an
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
11:00pm, Wednesday, 10'th Feb 2021
RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today an
Why AzurRx BioPharma, Usana Health Are Moving Today
11:47am, Wednesday, 10'th Feb 2021
Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates
CGIX Stock Price Increases Over 240% Pre-Market: Why It Happened
06:01am, Wednesday, 10'th Feb 2021
The stock price of Cancer Genetics Inc (NASDAQ: CGIX) is trading at over 240% pre-market as of 5:45 AM ET. This is why it happened.
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
05:16pm, Monday, 01'st Feb 2021
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today an
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
04:02pm, Thursday, 28'th Jan 2021
RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today an
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
04:05pm, Thursday, 07'th Jan 2021
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, C
SHAREHOLDER ALERT: WeissLaw LLP Investigates Cancer Genetics, Inc.
05:31pm, Thursday, 12'th Nov 2020
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. ("CGIX" or the
Cancer Genetics Reports Third Quarter 2020 Financial Results
04:25pm, Thursday, 12'th Nov 2020
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announce
Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-on
Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million
09:55pm, Wednesday, 28'th Oct 2020
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, anno
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
05:54pm, Wednesday, 28'th Oct 2020
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services, a
